Cystic Fibrosis Program

About Porosome Therapeutics

Porosome Therapeutics is a private, preclinical-stage biotech founded in 2018 and based in San Diego. The company's core platform is built upon the foundational discovery of the porosome, a nanomachine responsible for cellular secretion, which it aims to structurally elucidate and therapeutically modulate using an integrated cryo-EM and AI approach. Its lead programs target the underlying secretory dysfunction in Alzheimer's disease and cystic fibrosis, proposing a novel mechanism beyond current standards of care. The company is pre-revenue and positioned at the intersection of structural biology, AI-driven drug discovery, and nanomachine therapeutics.

About Vast Therapeutics

Vast Therapeutics is a private, pre-revenue biotech focused on a significant unmet need in chronic respiratory diseases, which affect over 500 million people globally. The company has advanced its lead candidate into Phase 1 clinical trials and has secured non-dilutive grant funding and Orphan Drug Designation, validating its approach. Its pipeline targets specific infections and inflammatory pathways in conditions like cystic fibrosis and bronchiectasis, aiming to improve quality of life and reduce hospitalizations. The company is currently raising capital through a public Reg CF funding round.

Therapeutic Areas

Other Cystic Fibrosis Drugs